

3rd Floor 16c3

Docket No. SCH 1655

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


IN RE APPLICATION OF: Klaus STOCKEMANN et al.

GAU: 1654

SERIAL NO: 09/117,357

EXAMINER: C. Delacroix-Muirheid

FILING DATE: September 22, 1998

FOR: PHARMACEUTICAL COMBINED PREPARATION AND ITS USE IN THE TREATMENT OF
GYNAECOLOGICAL DISORDERS

AMENDMENT TRANSMITTAL

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RECEIVED

AUG 02 2001


TECH CENTER 1600/2900

SIR:

Transmitted herewith is an amendment in the above-identified application.


- ☐ No additional fee is required.
- ☐ Applicant(s) is/are entitled to small entity status.
- ☐ Additional documents filed herewith:

The fee has been calculated below:

CLAIMS	CLAIMS REMAINING		HIGHEST NO. PREVIOUSLY PAID FOR	NO. OF EXTRA CLAIMS	RATE		CALCULATIONS
TOTAL	25	MINUS	20	5	x	\$18 =	\$90.00
INDEPENDENT	2	MINUS	3	0	x	\$80 =	\$0.00
	<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS						
	TOTAL OF ABOVE CALCULATIONS						\$0.00
	<input type="checkbox"/>						
	<input type="checkbox"/> REDUCTION BY 50% FOR FILING BY SMALL ENTITY						\$0.00
	<input type="checkbox"/> RECORDATION OF ASSIGNMENT				+	\$40 =	\$0.00
TOTAL						\$90.00	

- ☒ A check in the amount of \$90.00 is attached.
- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 13-3402. A duplicate copy of this sheet is enclosed.
- ☒ If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. § 1.136, and any additional fees required under 37 C.F.R. § 1.36 for any necessary extension of time may be charged to Deposit Account No. 13-3402. A duplicate copy of this sheet is enclosed.

Respectfully submitted,


 Brian P. Heaney, Registration No. 32,542
 Attorney for Applicants

MILLEN, WHITE, ZELANO
 & BRANIGAN, P.C.
 Arlington Courthouse Plaza I
 2200 Clarendon Blvd. Suite 1400
 Arlington, Virginia 22201
 Telephone: (703) 243-6333
 Facsimile: (703) 243-6410
 Date: July 30, 2001

BPH:imm\K:\Sch\1655\Amend Transm 7-30-01.docm 7-30-01

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

AUG 02 2001

In re Application of:

TECH CENTER 1600/2900

Klaus STÖCKEMANN et al


Art Unit: 1654

Serial No.: 09/117,357

Examiner: C. Delacroix-Muirheid

Filed: September 22, 1998

Title: PHARMACEUTICAL COMBINED PREPARATION AND ITS USE IN THE
TREATMENT OF GYNAECOLOGICAL DISORDERS



SUPPLEMENTAL AMENDMENT

Sir:

Please amend the above-identified application as follows:

IN THE CLAIMS:

Please add the following new claims 44-50 as follows:

44. A method of inhibiting LHRH analog-induced detrimental side effects due to the administration of an LHRH analog to a patient, wherein said detrimental side effect is reduction in bone density, comprising administering to a patient in need thereof an effective amount of anti-estrogen wherein said anti-estrogen is Raloxifen.

45. A method according to claim 44, wherein said patient is a woman.

46. A method according to claim 45, wherein said anti-estrogen is administered orally.

47. A method according to claim 44, wherein said LHRH analog is Leuprorelin, Buserelin or Zoladex.

48. A pharmaceutical composition comprising Raloxifen and an LHRH analog.

49. A pharmaceutical composition according to claim 48, wherein said LHRH analog is Leuprorelin, Buserelin or Zoladex.

50. A composition according to claim 48, wherein said composition is in the form of a depot formulation.

08/01/2001 MWOLDER1 00000121 09117357

01 FC:103

90.00 DP